Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

210 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Correction to: A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial.
Devos T, Geukens T, Schauwvlieghe A, Ariën KK, Barbezange C, Cleeren M, Compernolle V, Dauby N, Desmecht D, Grimaldi D, Lambrecht BN, Luyten A, Maes P, Moutschen M, Romano M, Seyler L, Nevessignsky MT, Vandenberghe K, van Griensven J, Verbeke G, Vlieghe E, Yombi JC, Liesenborghs L, Verhamme P, Meyfroidt G. Devos T, et al. Among authors: yombi jc. Trials. 2020 Dec 14;21(1):1024. doi: 10.1186/s13063-020-04947-2. Trials. 2020. PMID: 33317581 Free PMC article. No abstract available.
A randomized, multicentre, open-label phase II proof-of-concept trial investigating the clinical efficacy and safety of the addition of convalescent plasma to the standard of care in patients hospitalized with COVID-19: the Donated Antibodies Working against nCoV (DAWn-Plasma) trial.
Devos T, Geukens T, Schauwvlieghe A, Ariën KK, Barbezange C, Cleeren M, Compernolle V, Dauby N, Desmecht D, Grimaldi D, Lambrecht BN, Luyten A, Maes P, Moutschen M, Romano M, Seyler L, Nevessignsky MT, Vandenberghe K, van Griensven J, Verbeke G, Vlieghe E, Yombi JC, Liesenborghs L, Verhamme P, Meyfroidt G. Devos T, et al. Among authors: yombi jc. Trials. 2020 Nov 27;21(1):981. doi: 10.1186/s13063-020-04876-0. Trials. 2020. PMID: 33246499 Free PMC article. Clinical Trial.
Clinical characteristics and outcomes of COVID-19 in people living with HIV in Belgium: A multicenter, retrospective cohort.
Nasreddine R, Florence E, Moutschen M, Yombi JC, Goffard JC, Derdelinckx I, Lacor P, Vandekerckhove L, Messiaen P, Vandecasteele S, Delforge M, De Wit S; Belgian Research on AIDS and HIV Consortium (BREACH). Nasreddine R, et al. Among authors: yombi jc. J Med Virol. 2021 May;93(5):2971-2978. doi: 10.1002/jmv.26828. Epub 2021 Feb 9. J Med Virol. 2021. PMID: 33506953 Free PMC article.
Population Pharmacokinetics of Hydroxychloroquine in COVID-19 Patients: Implications for Dose Optimization.
Thémans P, Belkhir L, Dauby N, Yombi JC, De Greef J, Delongie KA, Vandeputte M, Nasreddine R, Wittebole X, Wuillaume F, Lescrainier C, Verlinden V, Kiridis S, Dogné JM, Hamdani J, Wallemacq P, Musuamba FT. Thémans P, et al. Among authors: yombi jc. Eur J Drug Metab Pharmacokinet. 2020 Dec;45(6):703-713. doi: 10.1007/s13318-020-00648-y. Eur J Drug Metab Pharmacokinet. 2020. PMID: 32968954 Free PMC article.
A public health value-based healthcare paradigm for HIV.
Vermeersch S, Demeester RP, Ausselet N, Callens S, De Munter P, Florence E, Goffard JC, Henrard S, Lacor P, Messiaen P, Libois A, Seyler L, Uurlings F, Vandecasteele SJ, Van Wijngaerden E, Yombi JC, Annemans L, De Wit S. Vermeersch S, et al. Among authors: yombi jc. BMC Health Serv Res. 2022 Jan 2;22(1):13. doi: 10.1186/s12913-021-07371-7. BMC Health Serv Res. 2022. PMID: 34974833 Free PMC article.
Impact of COVID-19 on the Belgian HIV epidemic: slowdown of HIV transmission and testing and adaptation of care.
Van Beckhoven D, Serrien B, Montourcy M, Verhofstede C, Van den Bossche D, Libois A, De Geyter D, Martin T, Van den Eynde S, Vuylsteke B, Darcis G, van Halem K, Florence E, Deblonde J; Belgian Research on AIDS and HIV Consortium (BREACH). Van Beckhoven D, et al. BMC Infect Dis. 2022 Dec 3;22(1):901. doi: 10.1186/s12879-022-07879-1. BMC Infect Dis. 2022. PMID: 36463126 Free PMC article.
Prevalence and epidemiology of HIV type 1 drug resistance among newly diagnosed therapy-naive patients in Belgium from 2003 to 2006.
Vercauteren J, Derdelinckx I, Sasse A, Bogaert M, Ceunen H, De Roo A, De Wit S, Deforche K, Echahidi F, Fransen K, Goffard JC, Goubau P, Goudeseune E, Yombi JC, Lacor P, Liesnard C, Moutschen M, Pierard D, Rens R, Schrooten Y, Vaira D, van den Heuvel A, van der Gucht B, van Ranst M, van Wijngaerden E, Vandercam B, Vekemans M, Verhofstede C, Clumeck N, Vandamme AM, van Laethem K. Vercauteren J, et al. Among authors: yombi jc. AIDS Res Hum Retroviruses. 2008 Mar;24(3):355-62. doi: 10.1089/aid.2007.0212. AIDS Res Hum Retroviruses. 2008. PMID: 18327983
A CARD9 Founder Mutation Disrupts NF-κB Signaling by Inhibiting BCL10 and MALT1 Recruitment and Signalosome Formation.
De Bruyne M, Hoste L, Bogaert DJ, Van den Bossche L, Tavernier SJ, Parthoens E, Migaud M, Konopnicki D, Yombi JC, Lambrecht BN, van Daele S, Alves de Medeiros AK, Brochez L, Beyaert R, De Baere E, Puel A, Casanova JL, Goffard JC, Savvides SN, Haerynck F, Staal J, Dullaers M. De Bruyne M, et al. Among authors: yombi jc. Front Immunol. 2018 Oct 31;9:2366. doi: 10.3389/fimmu.2018.02366. eCollection 2018. Front Immunol. 2018. PMID: 30429846 Free PMC article.
Eosinopenia and COVID-19 patients: So specific ?
Andreozzi F, Hermans C, Yombi JC. Andreozzi F, et al. Among authors: yombi jc. EClinicalMedicine. 2020 Jun 27;24:100439. doi: 10.1016/j.eclinm.2020.100439. eCollection 2020 Jul. EClinicalMedicine. 2020. PMID: 32632419 Free PMC article. No abstract available.
210 results